ClinicalTrials.gg
CompletedNCT01818596Updated Mar 2, 2020Results posted

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

A Phase 3 interventional study of E/C/F/TAF in HIV and HIV Infections, sponsored by Gilead Sciences. Completed at 70 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-02.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing elvitegravir in HIV Infections — none open to participants now, none under way, none of them phase 3. elvitegravir · HIV Infections.

Enrollment
6th of 11
252 · median 252
Started
2013
with 6 others
Phase 3
7 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
11 of 11
Gilead Sciences

Among the 11 studies testing elvitegravir in HIV Infections, this one is the 6th largest by enrollment, is one of 7 that started in 2013, is one of 7 in phase 3, and was the 7th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 11 studies testing elvitegravir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About elvitegravir

elvitegravir: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing elvitegravir in HIV Infections as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and treatment-experienced HIV-positive, adults with mild to moderate renal impairment.

03

Conditions studied

  • HIV
  • HIV Infections

Browse trials for

Keywords

  • HIV
  • HIV-1 Infected
  • Treatment Experienced
  • Treatment Naive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Cohort 1 (treatment-experienced switch)

  • Must not have a history of known resistance to elvitegravir (EVG), tenofovir disoproxil fumarate (TDF), or emtricitabine (FTC)
  • Plasma -1 RNA concentrations (at least two measurements) at undetectable levels (according to the local assay being used) in the 6 months preceding the screening visit and have HIV-1 RNA \< 50 copies/mL at screening
  • Estimated (GFR) 30-69 mL/min according to the formula for creatinine clearance, using actual weight
  • May be currently enrolled in Gilead studies GS-US-236-0102, GS-US-236-0103, and GS-US-216-0114, but will be eligible to enroll only after the Week 144 visit for that study is complete; or currently receiving Stribild® (STB) or atazanavir (ATV)/cobicistat (COBI) + Truvada (TVD) in Gilead studies GS-US-236-0104 or GS-US-216-0105, but will be eligible to enroll only after the Week 48 visit for that study is complete.

Cohort 2 (treatment-naive)

  • Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
  • Screening genotype report provided by Gilead Sciences must show sensitivity to EVG, FTC, and TDF
  • No prior use of any approved or antiretroviral drug for any length of time, except the use for pre-exposure prophylaxis (PrEP), or post-exposure prophylaxis (PEP), up to 6 months prior to screening
  • Estimated GFR 30-69 mL/min according to the Cockcroft Gault formula for creatinine clearance, using actual weight

All Cohorts:

All individuals must meet all of the following inclusion criteria to be eligible for participation in this study:

  • The ability to understand and sign a written form, which must be obtained prior to initiation of study procedures
  • of ≥ 50 cells/μL
  • Stable renal function: serum creatinine measurements to be taken at least once (within three months of screening)
  • Cause of underlying chronic kidney disease (eg hypertension, diabetes) stable, without change in medical management, for 3 months prior to baseline
  • Normal (ECG)
  • Hepatic transaminases ( and ALT) ≤ 5 x (ULN)
  • Total ≤ 1.5 mg/dL, or normal direct bilirubin
  • Adequate hematologic function
  • Serum amylase ≤ 5 x ULN
  • Females of must agree to utilize highly effective methods (two separate forms of contraception, one of which must be an effective barrier method, or be non-heterosexually active, practice sexual abstinence) from screening throughout the duration of study treatment and for 30 days following the last dose of study drug
  • Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing
  • Males must agree to utilize a highly effective method of contraception during heterosexual intercourse throughout the study period and for 30 days following discontinuation of investigational medicinal product. A highly effective method of contraception is defined as two separate forms of contraception, one of which must be an effective barrier method, or males must be non-heterosexually active, or practice sexual abstinence

Key Exclusion Criteria:

  • A new AIDS-defining condition (excluding CD4 cell count and percentage criteria) diagnosed within the 30 days prior to screening,with the exception of the first two bullet points
  • virus (HCV) antibody positive. Individuals who are HCV positive, but have a documented negative HCV RNA, are eligible
  • surface antigen (HBVsAg) positive
  • Individuals receiving drug treatment for Hepatitis C, or individuals who are anticipated to receive treatment for Hepatitis C during the course of the study
  • Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, etc.)
  • Females who are breastfeeding
  • Positive serum pregnancy test
  • Have an implanted defibrillator or pacemaker
  • Current alcohol or substance use judged by the Investigator to potentially interfere with study compliance
  • A history of within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline
  • Individuals on hemodialysis, other forms of renal replacement therapy, or on treatment for underlying kidney diseases (including prednisolone and dexamethasone)
  • Individuals receiving ongoing therapy with any medications not to be used with EVG, COBI, FTC, or TAF or individuals with any known allergies to the of E/C/F/TAF

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    E/C/F/TAF

    Participants will receive E/C/F/TAF for 144 weeks. Following Week 144, in countries where E/C/F/TAF is not available (except for the United Kingdom), participants will be given the option to continue in the study and receive E/C/F/TAF for another 48 weeks, or until the product becomes available through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever comes first.

    Drug: E/C/F/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24

    eGFR is a measurement of the kidney's ability to filter blood.

    Time frame: Baseline; Week 24

  2. Change From Baseline in eGFR Calculated by the Chronic Kidney Disease Epidemiology Collaboration Method Based on Cystatin C (eGFR_CKD-EPI,cysC) at Week 24

    eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex.

    Time frame: Baseline; Week 24

  3. Change From Baseline in eGFR Calculated by the CKD-EPI Method Based on Serum Creatinine (eGFR_CKD-EPI,Creatinine) at Week 24

    eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex.

    Time frame: Baseline; Week 24

Secondary outcomes

  1. Change From Baseline in Actual GFR (aGFR) of E/C/F/TAF for Participants Enrolled in the PK/PD Substudy

    aGFR was directly measured using iohexol plasma clearance (CLiohexol).

    Time frame: Baseline; Week 2, 4, or 8; Week 24

  2. Percent Change From Baseline in C-type Collagen Sequence (CTX) at Weeks 24 and 48

    CTX is a biomarker of bone turnover.

    Time frame: Baseline; Weeks 24 and 48

  3. Percent Change From Baseline in Procollagen Type 1 N-terminal Propeptide (P1NP) at Weeks 24 and 48

    P1NP is a biomarker of bone turnover.

    Time frame: Baseline; Weeks 24 and 48

  4. Percent Change From Baseline in Retinol Binding Protein (RBP) to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144

    Urine RBP is a renal biomarker which is used to evaluate drug-induced kidney injury.

    Time frame: Baseline; Weeks 24, 48, 96, and 144

  5. Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144

    Urine beta-2-microglobulin is a renal biomarker which is used to evaluate drug-induced kidney injury.

    Time frame: Baseline; Weeks 24, 48, 96, and 144

  6. Percentage of Participants Experiencing Adverse Events or Graded Laboratory Abnormalities

    Adverse events (AEs) and graded laboratory abnormalities occurring during the E/C/F/TAF treatment period were summarized across the participant population. A participant was counted once if they had a qualifying event.

    Time frame: Baseline up to Week 240 plus 30 days

  7. Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Weeks 24, 48, 96, and 144

    The percentage of participants achieving HIV-1 RNA \< 50 Copies/mL at Weeks 24, 48, 96, and 144 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Weeks 24, 48, 96, and 144

  8. Pharmacokinetic (PK) Parameter: Cmax of TAF

    Cmax is defined as the maximum concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  9. PK Parameter: Tmax of TAF

    Tmax is defined as the time of Cmax. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  10. PK Parameter: Clast of TAF

    Clast is defined as the last observable concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  11. PK Parameter: Tlast of TAF

    Tlast is defined as the time of Clast. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  12. PK Parameter: λz of TAF

    λz is defined as the terminal elimination rate constant. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  13. PK Parameter: AUCtau of TAF

    AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  14. PK Parameter: t1/2 of TAF

    t1/2 is defined as the estimate of the terminal elimination half-life of the drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  15. PK Parameter: AUCtau of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cell (PBMC) for Participants Enrolled in PK/PD Sub-study

    TFV-DP is an active phosphorylated metabolite of tenofovir alafenamide. AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

    Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose

  16. Change From Baseline in the eGFR_CG at Weeks 48, 96, and 144

    eGFR is a measurement of the kidney's ability to filter blood.

    Time frame: Baseline; Weeks 48, 96, and 144

  17. Change From Baseline in eGFR_CKD-EPI,cysC at Weeks 48, 96, and 144

    eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex.

    Time frame: Baseline; Weeks 48, 96, and 144

  18. Change From Baseline in eGFR_CKD-EPI,Creatinine at Weeks 48, 96, and 144

    eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex.

    Time frame: Baseline; Weeks 48, 96, and 144

07

Results

Posted Feb 18, 2016
Limitations and caveats
Enrollment in Cohort 2 (treatment-naive) was low, which affects the interpretation of the data.

Participant flow

Participants were enrolled at study sites in North America, Australia, Asia, and Europe. The first participant was screened on 27 March 2013. The last study visit occurred on 18 July 2018.

Participant flow — Overall Study
MilestoneCohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Started2466
Completed2156
Not completed310
Withdrew: Enrolled but not treated40
Withdrew: Adverse event70
Withdrew: Death30
Withdrew: Investigator's discretion40
Withdrew: Protocol violation10
Withdrew: Withdrew consent50
Withdrew: Lost to follow-up70

Outcome measures

PrimaryChange From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24

eGFR is a measurement of the kidney's ability to filter blood.

Time frame:
Baseline; Week 24
Reported as:
Median · mL/min
Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24
mL/minCohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Baseline55.6 (45.7 to 62.4)60.2 (45.0 to 63.2)
Change at Week 24-0.4 (-4.7 to 4.5)-0.3 (-3.6 to 1.3)
PrimaryChange From Baseline in eGFR Calculated by the Chronic Kidney Disease Epidemiology Collaboration Method Based on Cystatin C (eGFR_CKD-EPI,cysC) at Week 24

eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex.

Time frame:
Baseline; Week 24
Reported as:
Median · mL/min/1.73 m^2
Change From Baseline in eGFR Calculated by the Chronic Kidney Disease Epidemiology Collaboration Method Based on Cystatin C (eGFR_CKD-EPI,cysC) at Week 24
mL/min/1.73 m^2Cohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Baseline69.7 (55.9 to 82.7)70.2 (64.0 to 100.8)
Change at Week 243.8 (-4.8 to 11.2)3.9 (-3.3 to 13.2)
PrimaryChange From Baseline in eGFR Calculated by the CKD-EPI Method Based on Serum Creatinine (eGFR_CKD-EPI,Creatinine) at Week 24

eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex.

Time frame:
Baseline; Week 24
Reported as:
Median · mL/min/1.73 m^2
Change From Baseline in eGFR Calculated by the CKD-EPI Method Based on Serum Creatinine (eGFR_CKD-EPI,Creatinine) at Week 24
mL/min/1.73 m^2Cohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Baseline54.1 (46.0 to 62.8)54.4 (41.7 to 81.4)
Change at Week 24-1.8 (-6.1 to 4.9)-2.6 (-11.1 to -0.9)
SecondaryChange From Baseline in Actual GFR (aGFR) of E/C/F/TAF for Participants Enrolled in the PK/PD Substudy

aGFR was directly measured using iohexol plasma clearance (CLiohexol).

Time frame:
Baseline; Week 2, 4, or 8; Week 24
Reported as:
Mean · mL/min
Change From Baseline in Actual GFR (aGFR) of E/C/F/TAF for Participants Enrolled in the PK/PD Substudy
mL/minSubstudy Participants
Baseline60.1 ± 19.06
Change at Week 2, 4, or 8-0.6 ± 8.45
Change at Week 241.4 ± 9.91
Statistical analysis
  • Substudy Participants · Difference in glsm ratio: 98.94 · 90% CI 93.71 to 104.46A parametric analysis of variance model using a mixed-effects model with repeated statement was fitted to the natural logarithm transferred aGFR obtained at postbaseline visits and baseline.
  • Substudy Participants · Difference in glsm ratio: 102.66 · 90% CI 97.11 to 108.53A parametric analysis of variance model using a mixed-effects model with repeated statement was fitted to the natural logarithm transferred aGFR obtained at postbaseline visits and baseline.
SecondaryPercent Change From Baseline in C-type Collagen Sequence (CTX) at Weeks 24 and 48

CTX is a biomarker of bone turnover.

Time frame:
Baseline; Weeks 24 and 48
Reported as:
Median · percentage change
Percent Change From Baseline in C-type Collagen Sequence (CTX) at Weeks 24 and 48
percentage changeCohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Change at Week 24-3.9 (-15.8 to 10.7)16.9 (0.0 to 21.7)
Change at Week 48-2.2 (-16.7 to 24.4)0.0 (-4.8 to 10.8)
SecondaryPercent Change From Baseline in Procollagen Type 1 N-terminal Propeptide (P1NP) at Weeks 24 and 48

P1NP is a biomarker of bone turnover.

Time frame:
Baseline; Weeks 24 and 48
Reported as:
Median · percentage change
Percent Change From Baseline in Procollagen Type 1 N-terminal Propeptide (P1NP) at Weeks 24 and 48
percentage changeCohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Change at Week 24-12.98 (-34.48 to 8.86)6.44 (-5.08 to 47.62)
Change at Week 48-25.29 (-45.98 to 2.00)2.27 (-29.12 to 41.80)
SecondaryPercent Change From Baseline in Retinol Binding Protein (RBP) to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144

Urine RBP is a renal biomarker which is used to evaluate drug-induced kidney injury.

Time frame:
Baseline; Weeks 24, 48, 96, and 144
Reported as:
Median · percentage change
Percent Change From Baseline in Retinol Binding Protein (RBP) to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144
percentage changeCohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Change at Week 24-56.2 (-90.0 to -11.8)68.8 (-37.1 to 72.6)
Change at Week 48-68.9 (-92.2 to -20.5)47.8 (13.3 to 78.9)
Change at Week 96-64.1 (-91.4 to 9.8)55.0 (-10.5 to 197.0)
Change at Week 144-63.8 (-92.4 to 4.6)-1.0 (-10.2 to 43.4)
SecondaryPercent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144

Urine beta-2-microglobulin is a renal biomarker which is used to evaluate drug-induced kidney injury.

Time frame:
Baseline; Weeks 24, 48, 96, and 144
Reported as:
Median · percentage change
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144
percentage changeCohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Change at Week 24-70.7 (-92.6 to -11.1)-19.5 (-93.0 to 81.3)
Change at Week 48-76.5 (-94.6 to -17.7)-59.2 (-85.0 to 34.3)
Change at Week 96-83.6 (-96.4 to -31.1)-45.9 (-95.8 to 195.6)
Change at Week 144-81.9 (-95.5 to -18.0)-3.6 (-66.7 to 73.5)
SecondaryPercentage of Participants Experiencing Adverse Events or Graded Laboratory Abnormalities

Adverse events (AEs) and graded laboratory abnormalities occurring during the E/C/F/TAF treatment period were summarized across the participant population. A participant was counted once if they had a qualifying event.

Time frame:
Baseline up to Week 240 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Adverse Events or Graded Laboratory Abnormalities
percentage of participantsCohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Any AE95.5100.0
Grade 3 or 4 AE22.316.7
AE leading to drug discontinuation5.00
Serious AE22.716.7
Grade 3 or 4 laboratory abnormality42.666.7
SecondaryPercentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Weeks 24, 48, 96, and 144

The percentage of participants achieving HIV-1 RNA \< 50 Copies/mL at Weeks 24, 48, 96, and 144 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Weeks 24, 48, 96, and 144
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Weeks 24, 48, 96, and 144
percentage of participantsCohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Week 2495.083.3
Week 4893.0100.0
Week 9688.4100.0
Week 14481.4100.0
SecondaryPharmacokinetic (PK) Parameter: Cmax of TAF

Cmax is defined as the maximum concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

Time frame:
Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
Reported as:
Mean · ng/mL
Pharmacokinetic (PK) Parameter: Cmax of TAF
ng/mLSubstudy Participants
Pharmacokinetic (PK) Parameter: Cmax of TAF269.8 ± 180.77
SecondaryPK Parameter: Tmax of TAF

Tmax is defined as the time of Cmax. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

Time frame:
Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
Reported as:
Median · hours
PK Parameter: Tmax of TAF
hoursSubstudy Participants
PK Parameter: Tmax of TAF0.97 (0.50 to 1.98)
SecondaryPK Parameter: Clast of TAF

Clast is defined as the last observable concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

Time frame:
Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
Reported as:
Mean · ng/mL
PK Parameter: Clast of TAF
ng/mLSubstudy Participants
PK Parameter: Clast of TAF7.6 ± 25.73
SecondaryPK Parameter: Tlast of TAF

Tlast is defined as the time of Clast. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

Time frame:
Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
Reported as:
Median · hours
PK Parameter: Tlast of TAF
hoursSubstudy Participants
PK Parameter: Tlast of TAF4.45 (3.82 to 5.00)
SecondaryPK Parameter: λz of TAF

λz is defined as the terminal elimination rate constant. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

Time frame:
Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
Reported as:
Mean · 1/hour
PK Parameter: λz of TAF
1/hourSubstudy Participants
PK Parameter: λz of TAF1.764 ± 1.4521
SecondaryPK Parameter: AUCtau of TAF

AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

Time frame:
Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
Reported as:
Mean · ng*h/mL
PK Parameter: AUCtau of TAF
ng*h/mLSubstudy Participants
PK Parameter: AUCtau of TAF368.4 ± 631.20
SecondaryPK Parameter: t1/2 of TAF

t1/2 is defined as the estimate of the terminal elimination half-life of the drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

Time frame:
Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
Reported as:
Median · hours
PK Parameter: t1/2 of TAF
hoursSubstudy Participants
PK Parameter: t1/2 of TAF0.43 (0.37 to 0.52)
SecondaryPK Parameter: AUCtau of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cell (PBMC) for Participants Enrolled in PK/PD Sub-study

TFV-DP is an active phosphorylated metabolite of tenofovir alafenamide. AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.

Time frame:
Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
Reported as:
Mean · µmol*h/L
PK Parameter: AUCtau of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cell (PBMC) for Participants Enrolled in PK/PD Sub-study
µmol*h/LSubstudy Participants
PK Parameter: AUCtau of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cell (PBMC) for Participants Enrolled in PK/PD Sub-study50.6 ± 55.75
SecondaryChange From Baseline in the eGFR_CG at Weeks 48, 96, and 144

eGFR is a measurement of the kidney's ability to filter blood.

Time frame:
Baseline; Weeks 48, 96, and 144
Reported as:
Median · mL/min
Change From Baseline in the eGFR_CG at Weeks 48, 96, and 144
mL/minCohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Baseline55.6 (45.7 to 62.4)60.2 (45.0 to 63.2)
Change at Week 48-0.6 (-5.4 to 5.4)-0.6 (-1.9 to 4.2)
Change at Week 960.6 (-4.6 to 7.2)-1.9 (-4.0 to 6.0)
Change at Week 1441.5 (-4.8 to 7.2)7.0 (3.3 to 11.2)
SecondaryChange From Baseline in eGFR_CKD-EPI,cysC at Weeks 48, 96, and 144

eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex.

Time frame:
Baseline; Weeks 48, 96, and 144
Reported as:
Median · mL/min/1.73 m^2
Change From Baseline in eGFR_CKD-EPI,cysC at Weeks 48, 96, and 144
mL/min/1.73 m^2Cohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Baseline69.7 (55.9 to 82.7)70.2 (64.0 to 100.8)
Change at Week 481.7 (-7.3 to 12.0)7.3 (-0.1 to 12.2)
Change at Week 963.2 (-3.6 to 11.8)5.6 (-7.2 to 20.8)
Change at Week 1443.1 (-4.8 to 11.8)3.5 (-1.8 to 22.9)
SecondaryChange From Baseline in eGFR_CKD-EPI,Creatinine at Weeks 48, 96, and 144

eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex.

Time frame:
Baseline; Weeks 48, 96, and 144
Reported as:
Median · mL/min/1.73 m^2
Change From Baseline in eGFR_CKD-EPI,Creatinine at Weeks 48, 96, and 144
mL/min/1.73 m^2Cohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Baseline54.1 (46.0 to 62.8)54.4 (41.7 to 81.4)
Change at Week 48-1.7 (-7.9 to 4.2)-3.0 (-4.9 to 0.6)
Change at Week 960.1 (-5.7 to 6.4)-3.1 (-9.5 to 2.1)
Change at Week 1441.7 (-5.3 to 8.5)0.9 (-5.7 to 6.0)

Adverse events

Collected over First dose date up to Week 240 plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (Treatment-experienced)—55/242 (22.7%)195/242 (80.6%)
Cohort 2 (Treatment-naive)—1/6 (16.7%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventCohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
Suicidal ideationPsychiatric disorders0/2421/6
Acute myocardial infarctionCardiac disorders4/2420/6
PneumoniaInfections and infestations4/2420/6
DehydrationMetabolism and nutrition disorders3/2420/6
Cardiac failure congestiveCardiac disorders2/2420/6
Abdominal painGastrointestinal disorders2/2420/6
BronchitisInfections and infestations2/2420/6
GastroenteritisInfections and infestations2/2420/6
Type 2 diabetes mellitusMetabolism and nutrition disorders2/2420/6
ArthralgiaMusculoskeletal and connective tissue disorders2/2420/6
Most frequent other events
Showing 10 of 47
Most frequent other events
EventCohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)
HyperlipidaemiaMetabolism and nutrition disorders7/2422/6
Pain in extremityMusculoskeletal and connective tissue disorders25/2422/6
Supraventricular extrasystolesCardiac disorders1/2421/6
DiarrhoeaGastrointestinal disorders32/2421/6
Gingival painGastrointestinal disorders0/2421/6
Mouth ulcerationGastrointestinal disorders2/2421/6
Chest painGeneral disorders10/2421/6
FatigueGeneral disorders20/2421/6
Peripheral swellingGeneral disorders8/2421/6
BronchitisInfections and infestations37/2421/6

Baseline characteristics

Safety Analysis Set: participants were enrolled and received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Cohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)Total
Mean58 ± 9.955 ± 7.158 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)Total
Female50050
Male1926198
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)Total
Race — Asian34135
Race — American Indian or Alaska Native101
Race — Black or African American44347
Race — Native Hawaiian or Pacific Islander202
Race — White1522154
Race — Other707
Race — Not Permitted202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)Total
Ethnicity — Hispanic or Latino31132
Ethnicity — Not Hispanic or Latino2095214
Ethnicity — Not Permitted202
Region of Enrollment
Region of Enrollment(Participants)Cohort 1 (Treatment-experienced)Cohort 2 (Treatment-naive)Total
United States1665171
United Kingdom505
Thailand30131
Spain13013
Netherlands202
Dominican Republic606
Mexico202
Australia12012
France606
08

Study locations

70 sites
  • Maricopa Integrated Health System - McDowell Clinic
    Phoenix, Arizona 85006, United States
  • Pueblo Family Physicians
    Phoenix, Arizona 85015, United States
  • Health for Life Clinic PLLC
    Little Rock, Arkansas 72207, United States
  • Pacific Oaks Medical Group
    Beverly Hills, California 90211, United States
  • Kaiser Permanente
    Hayward, California 94545, United States
  • Long Beach Education and Research Consultants
    Long Beach, California 90813, United States
  • LA Gay & Lesbian Center - Jeffrey Goodman Special Care Clinic
    Los Angeles, California 90028, United States
  • Peter J Ruane, MD, Inc
    Los Angeles, California 90036, United States
  • Anthony Mills MD, Inc
    Los Angeles, California 90069, United States
  • Desert Medical Group Inc. dba Desert Oasis Healthcare Medical Group
    Palm Springs, California 92262, United States
  • Kaiser Permanente Medical Group
    Sacramento, California 95825, United States
  • Metropolis Medical
    San Francisco, California 94109, United States
  • Kaiser Permanente CTU San Francisco
    San Francisco, California 94118, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Dupont Circle Physician's Group
    Washington, District of Columbia 20009, United States
  • Gary J. Richmond, MD PA
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • Idocf/Valuhealthmd
    Orlando, Florida 32806, United States
  • University of South Florida
    Tampa, Florida 33602, United States
  • Triple O Research Institute, P.A.
    West Palm Beach, Florida 33401, United States
  • Rowan Tree Medical, P.A.
    Wilton Manors, Florida 33305, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia 30033, United States
  • Mercer University
    Macon, Georgia 31210, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Community Research Initiative of New England
    Boston, Massachusetts 02111, United States
  • The Research Institute
    Springfield, Massachusetts 01105, United States
  • Be Well Medical Center, P.C.
    Berkley, Michigan 48210, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • The Kansas City Care Clinic (KC Free Health Clinic)
    Kansas City, Missouri 64111, United States
  • Southampton Healthcare, Inc.
    Saint Louis, Missouri 63139, United States
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07754, United States
  • Saint Michael's Medical Center
    Newark, New Jersey 07102, United States
  • Southwest CARE Center
    Santa Fe, New Mexico 87505, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Upstate Infectious Diseases Associates
    Albany, New York 12208, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • North Shore University Hospital/Division of Infectious Diseases
    Manhasset, New York 11030, United States
  • Aids Care
    Rochester, New York 14607, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267-0405, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • University of PA HIV Clinical Trials Unit
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • St. Hope Foundation
    Bellaire, Texas 77401, United States
  • North Texas Infectious Diseases Consultants, PA
    Dallas, Texas 75246, United States
  • Garcias' Family Health Group
    Harlingen, Texas 78550, United States
  • Therapeutic Concepts, PA
    Houston, Texas 77004, United States
  • Gordon E. Crofoot MD, PA
    Houston, Texas 77098, United States
  • Peter Shalit, MD
    Seattle, Washington 98104, United States
  • Holdsworth House Medical Practice
    Darlinghurst, New South Wales 2010, Australia
  • Clinical Research Infectious Diseases Department- Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Prahran Market Clinic
    Prahran, Victoria 3181, Australia
  • Instituto Dominicano de Estudios Virologicos (IDEV)
    Santo Domingo, 99999, Dominican Republic
  • Hopital de la Croix Rousse
    Lyon, 69004, France
  • GHPS Service des maladies infectieuses et tropicales pavillon Laveran unité de recherche clinique
    Paris, 75651, France
  • Hospital Civil de Guadalajara Dr. Juan I. Menchaca
    Guadalajara, Jalisco 44340, Mexico
  • University Medical Center Utrecht
    Utrecht, 3584 CX, Netherlands
  • Hospital Universitari de Bellvitge
    Barcelona, 8907, Spain
  • Germans Trias i Pujol University Hospital
    Barcelona, 8916, Spain
  • Hospital La Paz
    Madrid, 28046, Spain
  • HIV-NAT, Thai Red Cross AIDS Research Centre
    Bangkok, 10330, Thailand
  • Faculty of Medicine Ramathibodi Hospital, Mahidol University
    Bangkok, 10400, Thailand
  • Department of Preventive and Social Medicine, Faculty of Medicine, Siriraj Hospital
    Bangkok, 10700, Thailand
  • Srinagarind Hospital, Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Brighton & Sussex University Hospitals NHS Trust
    Brighton, BN2 1ES, United Kingdom
  • Kings College London
    London, SE5 9RJ, United Kingdom
  • Chelsea and Westminster NHS Foundation Trust Hospital
    London, Sw10 9NH, United Kingdom
  • Central Manchester University Hospitals NHS foundation Trust
    Manchester, M13 0FH, United Kingdom
09

References and documents

Publications

  • Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce MW; GS-US-292-0112 Study Team. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):530-7. doi: 10.1097/QAI.0000000000000908. PubMed 26627107 ↗
  • Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):180-184. doi: 10.1097/QAI.0000000000001186. PubMed 27673443 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Jul 2014, 16 months.

Results were first posted in Feb 2016, 1 year 6 months after primary completion. A results delay was requested in Sep 2014.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 16 months is below that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2013
First posted
Mar 26, 2013
StartActual
Mar 27, 2013
Primary completionActual
Jul 31, 2014
CompletionActual
Jul 18, 2018
Results delay requested
Sep 16, 2014
Results first posted
Feb 18, 2016
Last update
Mar 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01818596
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 26, 2013
Start date
Mar 27, 2013
Primary completion
Jul 31, 2014
Completion
Jul 18, 2018
Results posted
Feb 18, 2016
Last update
Mar 2, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion